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Corticobasal degeneration (CBD) is an uncommon, sporadic, neurodegenerative disorder of mid- to late-adult life. We describe a
further example of the pathologic heterogeneity of this condition. A 71-year-old woman initially presented dysarthria, clumsiness,
progressive asymmetric bradykinesia, and rigidity in left arm. Rigidity gradually involved ipsilateral leg; postural instability with
falls, blepharospasm, and dysphagia subsequently developed. She has been previously diagnosed as unresponsive Parkinson’s
Disease. At our clinical examination, she presented left upper-arm-ﬁxed-dystonia, spasticity in left lower limb and pyramidal signs
(BabinskiandHoﬀmann).BrainMRIshowedasymmetriccorticalatrophyintherightfrontotemporalcortex.Neuropsychological
examination showed an impairment in visuospatial functioning, frontal-executive dysfunction, and hemineglect. This case
demonstrates that association of asymmetrical focal cortical and subcortical features remains the clinical hallmark of this
condition. There are no absolute markers for the clinical diagnosis that is complicated by the variability of presentation
involving also cognitive symptoms that are reviewed in the paper. Despite the diﬃculty of diagnosing CBD, somatosensory
evoked potentials, motor evoked potentials, long latency reﬂexes, and correlations between results on electroencephalography
(EEG) and electromyography (EMG) provide further support for a CBD diagnosis. These techniques are also used to identify
neurophysiological correlates of the neurological signs of the disease.
1.Introduction
Corticobasal degeneration (CBD) is an uncommon, spo-
radic, neurodegenerative disease described for the ﬁrst time
by Rebeiz et al. [1].Itcanbeassociatedwithanextraordinary
variety of motor, sensory, behavioural, and cognitive symp-
toms [2].
It is an asymmetrical parkinsonism aﬀecting a limb,
typically an arm: rigidity is the most common manifestation
of the parkinsonian syndrome followed by bradykinesia,
gait disorder (postural instability and falls), and tremor;
asymmetrical limb dystonia is common as well. Other car-
dinal signs include higher cortical dysfunctions such as
apraxia(limbmorecommonthanorofacial,eyelid-opening).
Dementia, progressive nonﬂuent aphasia, speech apraxia,
progressive-supranuclear-palsy- (PSP-) like syndrome and
posterior cortical atrophy syndrome are other presentations
of CBD [3, 4].
CBD is a tauopathy (characterised by abnormal deposi-
tion of the microtubule-associated protein tau), similar to
frontotemporal dementia and progressive supranuclear palsy
(PSP) [5].
The typical pathological ﬁndings in CBD include focal
asymmetriccorticalatrophy,nigraldegeneration,taupositive
neuronal,andgliallesionsinbothgrayandwhitematters[6].
To achieve more accurate clinical diagnosis, neuropsy-
chological, electrophysiological, and imaging methods could
be applied to diﬀerentiate this disease from the other parkin-
sonism syndromes [3, 4].
In comparison with other neurological diseases, the
symptoms of CBD are particularly diﬃcult to understand
and the patients have considerable diﬃculties in describing2 International Journal of Alzheimer’s Disease
their experience. A better understanding of the disease may
help clinicians to make diagnosis, providing patients with
comprehensive information about prognosis and diﬃculties
they will encounter during the course of the disease, improv-
ing their quality of life as well as their careers.
2.CaseReport
A 71-year-old woman, primary school graduate, formerly
farmhand, was referred to our Department of Neurology
with left rigid-akinetic syndrome and cognitive dysfunction.
She had no previous medical or family neurological
history; she just reported in the previous months frequent
falls and postural instability.
She initially presented with slowly progressive dysarthria
and speech abnormalities two years before. Cognitive symp-
toms included impairment of spoken-language production
and attention/concentration deﬁcits.
Several months later clumsiness and rigidity in her left
upper limb appeared. Her main complaint was diﬃculty in
usingherleftarmandhand,whichgraduallyprogressed.The
limb became severely rigid and adopted a dystonic posture
associated with pain and functional disability.
Her clinical features slowly deteriorated and, 1 year later,
involved also the left lower limb with gait disorder associated
to postural instability and falls. Subsequently, the patient
underwent brain MRI and 18F-ﬂuorodeoxyglucose-positron
emission tomography (PET).
Brain MRI showed moderate atrophy, more pronounced
on the right side. She has been previously diagnosed as
Parkinson’s Disease but with no response to levodopa or do-
paminergic medications.
Asymmetrical hypometabolism involving the right fron-
tal cortex was also conﬁrmed by PET.
Her clinical symptoms gradually progressed and, four
months later, blepharospasm and mild dysphagia appeared.
When she was admitted to our Neurological Cen-
tre, the neurological examination revealed: blepharospasm;
hypomimia and asmmetric bradykinesia; left upper-arm-
ﬁxed-dystonia; spasticity in left lower limb and pyramidal
signs (Babinski, Hoﬀmann, and grasp reﬂex); moderate
disturbance of gait with short steps, tendency to drag her left
leg, bradykinesia, and propulsion requiring assistance.
We performed a complete neuropsychological exami-
nation (for more details see Table 1). Mini Mental State
Examination score was 23/30. The other tests revealed
impairment in visuospatial abilities, severe visuospatial
neglect (Figure 1), constructional and ideomotor apraxia,
poor word ﬂuency with mild visual confrontation anomia,
and nonverbal oral apraxia. Learning and memory were
minimally aﬀected.
Brain MRI showed asymmetric cortical atrophy in the
right frontotemporal cortex (Figure 2).
No abnormalities were found on EEG examination, even
if, a deeper analysis showed a focal slow wave activity in the
right parietotemporal area.
Relatedtoclinicalfeatures,basedupondiagnosticcriteria
proposed by Boeve et al. [4], she has been diagnosed as
“corticobasal degeneration (CBD)”.
Figure 1: Neuropsychological examination show emineglect
(Raven’s colored matrices and barrage test) and constructional
apraxia (Rey-Osterrieth complex ﬁgure).
Figure 2: Axial, T2-weighted and ﬂuid-attenuated inversion recov-
ery (FLAIR), MRI images of the brain, demonstrating asymmetric
cortical atrophy in the right hemisphere of the patient.
The diagnosis was based on the gradual onset of a
parkinsonian disorder associated with cortical dysfunctions
and other supportive features such as cognitive dysfunction,
asymmetric atrophy on MRI imaging, and asymmetric
h y p o p e r f u s i o no nP E T .
3. DiscussionandReview of the Literature
3.1. Clinical Presentation. Clinically CBD begins in the sixth,
seventh, or eighth decade [7], with slight predilection for
women [8, 9]. Typically the primary symptoms develop in
a profoundly asymmetric way, aﬀecting either one arm or,
less frequently, a leg, which appears to be rigid, dystonic,
akinetic, or apraxic. Clinical features include a series of
motor, cognitive and neuropsychiatric symptoms, that canInternational Journal of Alzheimer’s Disease 3
Table 1: Complete neuropsychological examination performed by the patient.
Obtained score Cut-oﬀ Result
Rey Auditory Learning Test
Immediate recall 40 28,53 Normal
Delayed recall 8 4,69 Normal
Recognition recall 14/15, 4/30; accuracy % 95 92 Normal
Digits forward 5 7±2B e l o w n o r m a l
Digit backward 2 5±2B e l o w n o r m a l
Corsi span Forward 3 7±2B e l o w n o r m a l
Corsi span Backward 2 5±2B e l o w n o r m a l
Rey-Osterrieth Complex ﬁgure
delayed recall 2,5; correct 9,5 9,46 Normal
Barrage Test Dx (26/30); Sx (5/30) 59 Below normal
Time 95   >105  
Deux Barrage 5/13, 22/67; accuracy % 57 95 Below normal
Time 210   >133   Prolonged time of
execution
Rey-Osterrieth Complex ﬁgure Test 4,5; correct 7 28,87 Below normal
Ideomotor Praxia 8,5 9 Below normal
Buccofacial apraxia 10 9 Normal
Raven’s colored Matrices 6; correct 10,5 18,96 Below normal
Verbal Fluency
Phonetc cues 10; correct 18,6 17,35 Normal
Semantic cues 12; correct 14,3 10,3 Normal
Naming (B.A.D.A.) 24 28 Below normal
be explained by impairment of the cortical and subcortical
structures.
Motor symptoms include progressive asymmetric rigid-
akinetic parkinsonism usually involving the upper limbs,
without resting tremor [10], focal stimulus-sensitive or
action myoclonus [4, 11], blepharospasm, speech abnormal-
ities, gait disorder with postural instability and falls, and
asymmetric limb dystonia, generally of the upper limbs,
sometimes evolving towards the development of a dystonic
clenched ﬁst [3, 12].
Eye movements are usually preserved, although a delay
in the initiation of saccades may occur, in absence of pursuit
and optokinetic nystagmus impairment [13, 14].
Involvement of higher cortical functions results in often
symmetricideomotorapraxia,ﬁrstlyaﬀectingthelimb,then,
as the disease progresses, eyelid-opening, tongue, lips. The
alien-limb phenomenon, that is seen in 50% of the cases
[15], can be deﬁned as “a circumstance in which one of
the patient’s hands behaves in a way which the patient ﬁnds
foreign, alien or at least uncooperative”; it commonly co-
occurs with cortical sensory loss [11, 16].
Cognitive decline is a common feature of the disorder
[17], occasionally the presenting feature of the disease [18].
The prominent characteristics are impairment of spoken-
language production (typically nonﬂuent aphasia), frontal
executive impairment, calculation and visuospatial skills
impairment, whereas semantic and episodic memory may be
spared [17].
Neuropsychiatric symptoms may include depression,
apathy, anxiety, irritability, disinhibition, delusions, and
obsessive compulsive disorder [19].
3.2. Electrophysiology. Abnormalities on magnetoenceph-
alography [20], an exaggerated electromyographic-electro-
myographic (EMG-EMG) coherence [21], and an alteration
in cortical excitability evaluated by means of transcranial
magnetic stimulation (TMS) [22] were noted in patients
with CBD [23]. On the other hand, conventional elec-
troencephalography (EEG) may be normal when the ﬁrst
clinical symptoms appear, and often remains unchanged as
the disease progresses. Nevertheless, an unilateral slowing
may be evident in some patients, which may occasionally
generalise to the whole cortex as the disease evolves [24,
25]. In a study involving six patients, Vion-Dury and
coworkers, using a quantitative standard EEG (EEGq) with
spectralanalysis,foundindeedtheoccurrenceofseveralEEG
abnormalities (generally enhanced by hyperventilation or
intermittent photic stimulation), such as an increase of slow
rhythms (delta or theta frequency range) and occasionally
theoccurrenceofsharpwaves[25].Theseabnormalitieswere4 International Journal of Alzheimer’s Disease
lateralisedinﬁvepatients(moreoftenafterhyperventilation)
and were bilateral in one, conﬁrming the asymmetrical fea-
tures of CBD [25]. Moreover, Huang et al. showed that the
EEG recordings with jerk-locked back average do not present
any jerk-locked cortical potentials [23].
In CBD, the cortical sensory evoked potentials (SEPs)
are not enlarged as in cortical reﬂex myoclonus, and back-
averaged cortical potentials do not precede each myoclonic
jerk [26–28]. Clinical and imaging evidence suggests that the
localized parietal cortical damage is a pivotal factor for the
absence of a giant SEP in these patients [29]. An asymmetric
alternationofinhibitory andexcitatorybalanceatthelevelof
cortical neurons leading to a particularly enhanced cortical
excitability may moreover play an important role in the
generation of myoclonus [27, 28]. The loss of the inhibitory
input from the somatosensory cortex to the relatively
intact motor cortex, which results from the prominent
asymmetric parietal atrophy, may give rise to the asymmetric
hyperexcitable motor cortex without giant SEP [30, 31],
even-though the existence of an alternative hyper-excitable
thalamo-cortical pathway cannot be excluded [32]. In eﬀect,
motor cortex disinhibition has been clearly demonstrated
in CBD by means of TMS applied in several paradigms
in diﬀerent neurophysiological studies [32–34]. By applying
single pulse-TMS, Lu and coworkers discovered a relatively
higher motor evoked potential (MEP) amplitude and a
signiﬁcantly shorter cortical silent period in the aﬀected
hand of CBD patients [26]. They therefore supposed that the
relatively enlarged MEP may be explained postulating that
an increased number of motorneurons are being recruited
by the descending volleys from the motor cortex [26],
while the shorter silent periods may reﬂect mainly defective
inhibitory processes [32]. The result from paired pulse-TMS
studies also supported the last hypothesis [22, 23, 35]; for
example, Frasson et al. [22] showed that, in patients with
CBD, paired magnetic stimuli delivered at short (inhibitory)
interstimulus intervals (ISIs) invariably elicited enlarged
MEPs; moreover, asymmetric corticocortical disinhibition
[22, 36], as well as asymmetric TMS maps organization
[32, 37], has been observed in patients with CBD.
In conclusion, several mechanisms could explain this
abnormal motor cortical excitability, namely, loss of
inhibitory neurons in the cortex or thalamus, eﬀect of
morphological changes in cortical neurons mainly in the
somatosensory cortices, disruption of some neuronal cir-
cuits, or the existence of alternative cortical-subcortical
pathways [33, 38]. Further electrophysiological studies are
necessary to better circumstantiate these hypothesis.
3.3. Imaging in Corticobasal Degeneration. Morphologic
imaging of the brain, although normal in the early phases of
the disease, may demonstrate asymmetrical cortical atrophy,
in particular of the frontal and parietal lobe, more evident
contralaterally to the side most severely clinically aﬀected
[39, 40]. Asimmetrical atrophy in the basal ganglia, corpus
callosum, lateral ventricles, and cerebral peduncles may be
present.
Functional imaging studies might be useful in the dif-
ferential diagnosis of patients with suspected CBD, showing
asymmetrical hypoperfusion on SPECT and asymmetrical
hypometabolism on PET involving the parietal-frontal cor-
tex and basal ganglia [41].
Other neurodegenerative disorders sometimes overlap
the CBD, making its clinical diagnosis diﬃcult. All criteria
stress the combination of an akinetic-rigid syndrome with
apraxia, alien limb syndrome, and cortical sensory deﬁcits.
A universally recognized feature is the asymmetry of clinical
presentation, further corroborated by a contralateral asym-
metrical atrophy on the structural and hypometabolism on
the functional neuroimaging.
3.4. Neuropathology in Corticobasal Degeneration. Neuro-
pathologically CBD presents as asymmetrical focal atrophy
of the cerebral cortex focused on the peri-Rolandic posterior
frontal and parietal cortex, especially the motor and sensory
areas [42]. There is a relative sparing of temporal and occip-
ital cortex, except in some forms presenting with dementia
or primary progressive aphasia, which are characterised by a
more symmetric and more severe involvement of the frontal
and temporal lobes [6].
Basalgangliaarealsoinvolvedwithsubstantialatrophyin
the lateral two-thirds of the substantia nigra, and, to a lesser
extent, of putamen, pallidum, thalamus, and hypothalamus
[43].
Histologically CBD is characterised by large pale bal-
looned neurons (neuronal achromasia), with tau-positive
cytoplasmatic inclusions and astrocytic plaques (annular
clusters of tau-positive deposits within the distal processes
of astrocytes), typically distributed in atrophic cortices [5, 6,
42].
Molecularly CBD is a taupathy, characterised by accu-
mulation of abnormal ﬁlamentous inclusions of hyperphos-
phorylated tau-protein in neurons and glia, similarly to
progressive supranuclear palsy (PSP), and some forms of
frontotemporal dementia with parkinsonism (FTD) [5, 44].
This molecular overlap, especially with PSP is very argued,
and whether they are the extremities of the spectrum of
a single disorder or two diﬀerent disorders with a similar
genetic predisposition is not clear [3, 18].
3.5. Diagnostic Criteria and Growing Importance of Cog-
nitive Symptoms. The symptoms can be gathered in four
categories: natural history and presentation, motor, sensory
motor, and cognitive symptoms. The ﬁrst three categories
include characteristics which have been taken into account
in almost all the previous diagnostic criteria. Up to 1994,
dementia was an exclusion criterion of CBD; from 2003,
on the base of new criteria, cognitive impairments support
diagnosis, so the inclusion of the cognitive criteria reﬂects
the growing recognition of the importance of cognitive
assessment in the diagnosis of CBD [3, 45].
The core features of disease are insidious onset and
progressive course, no identiﬁable cause (tumor, infarct) of
symptomatology, cortical dysfunction includes at east one of
the following: (i) focal or asymmetric ideomotor apraxia, (ii)
alien-limb phenomena, (iii) cortical sensory loss, (iv) visual
or sensory hemineglect, constructional apraxia, (v) focalInternational Journal of Alzheimer’s Disease 5
or asymmetric myoclonus, (vi) apraxia of speech/nonﬂuent
aphasia: extrapyramidal dysfunction as reﬂected by one of
the following: (i) focal or asymmetrical appendicular rigidity
lacking prominent and sustained L-dopa response, (ii) focal
or asymmetrical appendicular dystonia.
The supportive investigations are variable degrees of
focal or lateralized cognitive dysfunction, with relative
preservationoflearningandmemory,onneuropsychometric
testing, focal or asymmetric atrophy on computed tomog-
raphy or magnetic resonance imaging, typically maximal in
parietofrontal cortex, focal or asymmetric hypoperfusion on
single-photon emission computed tomography and positron
emission tomography, typically maximal in parietofrontal
cortex/basal ganglia/thalamus [3].
3.6. Diﬀerential Diagnosis. Predominant parkinsonian fea-
tures might not be easy to distinguish from idiopathic PD
and atypical parkinsonian syndromes (e.g., PSP and mul-
tiple system atrophy, MSA). Akinetic-rigid syndrome, early
inbalance and poor response to dopaminergic treatment are
typical symptoms for CBP, PSP, and MSA, in contrast with
PD. PSP is clinically and pathologically related to CBD,
but with diﬀerences in symmetrical versus asymmetrical
parkinsonism, and in the pattern of rigidity, which tends
to be more nuchal/axial in PSP and more limb-accentuated
in CBD. Also, while the superanuclear gaze palsy can occur
in both conditions, in CBD it tends to aﬀect the horizontal
more than the vertical gaze and the saccade latency (delay in
initiating saccades) more than saccade velocity (the speed of
saccades).
In patients with cognitive presentation, the diagnosis
depends on the speciﬁc case: pronounced visuoper-ceptual
deﬁcits related to dementia with Lewy bodies (DLB), lan-
guage involvement to primary progressive aphasia (PPA),
and prominent behavioral features to frontotemporal de-
mentia (FTD) [3].
4. Conclusion
CBD can present with various clinical syndromes. The diag-
n o s i so ft h i sh e t e r o g e n e o u sd i s o r d e ri sd i ﬃcult and misdiag-
noses are frequent. It is important to explain the nature of
the motor as well as the cognitive deﬁcits to the patients as
well as to all people involved in their care.
As a motor disorder, CBD has been recognized for over
30 years. However, more recent ﬁndings suggest that there
is a neuropsychological syndrome associated with CBD. The
mostprominent neuropsychologicalfeaturesofCBDinclude
limb apraxia, ideomotor and ideational apraxias. Executive
function and language impairments are also reported.
The characterization of the natural history of patients
with the CBD (clinical, laboratory, neuropsychological, radi-
ological features) is important to improve the accuracy of
diagnosis.
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